Furthermore, Daratumumab effectively targets CD38 expressing myeloid-derived suppressor cells (MDSC) and regulatory T cells, which are known contributors to the formation of an immunosuppressive tumor microenvironment, thus promoting immune escape [34]. This evidence concerns the gene CD38 and neoplasm.